Subscribe to Newsletter
Subspecialties Cornea / Ocular Surface, Business and Innovation, Health Economics and Policy

Smarter DSAEK Surgery

sponsored by CorneaGen

CorneaGen first released its EndoSerter Corneal Endothelium Delivery Instrument in 2011, providing surgeons with a sterile, single-use device that offered a controlled method of delivering and positioning the donor allograft into the anterior chamber of the eye during Descemet’s stripping endothelial keratoplasty (DSEK). Donor tissue is inserted through a tight 4 mm clear corneal incision, reducing the need for sutures.

The EndoSerter’s intelligent design allows coaxial irrigation, eliminating the need for a separate chamber maintainer. Unlike conventional insertion devices, the EndoSerter does not push or pull on the fragile allograft tissue and endothelial cells; the allograft is simply uncovered during deployment.

CorneaGen works directly with each surgeon to identify their graft thickness needs.

Unsurprisingly, the EndoSerter was well-received by the ophthalmic community – and expectations are high for its successor. The latest device, the preloaded EndoSerter-PL, has been designed with automated procedures in mind – procedures which now represent the largest segment of all domestic corneal transplant cases in the US. The all-new EndoSerter-PL streamlines the process by acting as both a shipping container and insertion device. CorneaGen processes the tissue to the surgeon’s exact specifications and loads the graft into the EndoSerter-PL, saving precious time in the OR. In short, the preloaded EndoSerter-PL simplifies the DSAEK surgical procedure – better serving surgeons (improved procedure) and, ultimately, better serving patients.

But the service doesn’t stop there. CorneaGen works directly with each surgeon to identify their graft thickness needs. In response to demand for everthinner tissue, CorneaGen has developed Nano-Thin™ DSAEK – at less than 60 microns, it is the thinnest tissue on the market and a perfect accompaniment to the EndoSerter-PL, and just one example of how CorneaGen continues to pioneer the next generation of cornea care.

From new medical devices and biologics to therapeutics and interventions, CorneaGen continues to support corneal surgeons and their patients in the fight against preventable blindness. Available spring of 2021, the release of the newly refined preloaded EndoSerter-PL brings the company one step closer on its mission to eliminate corneal blindness by 2040.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Case Studies
The Missing Piece of the Dry Eye Puzzle

| Contributed by Quidel

Uncovering Ocular Comorbidity

| Contributed by Quidel

Finding Ocular Surface Inflammation

| Contributed by Quidel

Related Product Profiles
Subspecialties Cornea / Ocular Surface
Tear Osmolarity – Empowering. Established. Essential.

| Contributed by TearLab

Subspecialties Cornea / Ocular Surface
Preservative-Free Cyclosporine 0.1% Ophthalmic Emulsion

| Contributed by ImprimisRx

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: